RBC reiterates Gilead outperform rating

Gilead Sciences was rated by RBC Capital Markets analyst Jason Kantor at outperform, average risk, in anticipation of the company's second-quarter results. RBC's new earnings per share estimate is $0.59, up from $0.56, and forecasts higher HIV sales and strong IMS script trends. Shares of the Foster City, Calif.-based biopharmaceutical company were up $2.86, or 5.10%, at $58.95 on volume of 7,144,574 shares versus the three-month running average of 5,231,270 shares. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.